OABIHealthcare · BiotechnologyOABI Stock Forecast: OmniAb, Inc. Price Predictions for 2026-2027
The 7 Wall Street analysts covering OmniAb, Inc. hold a median 12-month price target of $8 — +308.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 85 of 100 as at 1 Aug 2026 — inside the top quartile. Here, the model and the Street point the same way.
OABI stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores OmniAb, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (91): Sales and profits are climbing, and climbing faster than before.
Issuance (51): The company has been issuing shares or taking on financing, diluting existing holders.
The rank is the raw material. Whether the rules would actually own OmniAb, Inc. — and when they’d sell — is the membership.
OABI stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on OABI, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +308.2% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 7 Aug 2025 | RBC Capital | Maintains | Outperform | $4.00 → $3.00 |
| 12 May 2025 | Benchmark | Reiterates | Buy | — |
| 27 Mar 2025 | RBC Capital | Maintains | Outperform | — |
| 20 Mar 2025 | Benchmark | Maintains | Buy | — |
| 19 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 14 Nov 2024 | Benchmark | Reiterates | Buy | — |
| 14 Nov 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 19 Aug 2024 | Benchmark | Reiterates | Buy | — |
| 16 Aug 2024 | RBC Capital | Reiterates | Outperform | — |
| 12 Aug 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 14 May 2024 | Benchmark | Reiterates | Buy | — |
| 26 Mar 2024 | Truist Securities | Maintains | Buy | — |
| 22 Mar 2024 | Benchmark | Reiterates | Buy | — |
| 21 Mar 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 21 Mar 2024 | RBC Capital | Reiterates | Outperform | — |
| 14 Nov 2023 | Benchmark | Reiterates | Buy | — |
| 11 Aug 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 12 May 2023 | Benchmark | Reiterates | Buy | — |
| 21 Apr 2023 | Benchmark | Initiates | Buy | — |
| 13 Apr 2023 | Craig-Hallum | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
OABI analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
OmniAb, Inc. (OABI) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- −3.5×
- Price / sales
- 9.9×
- Price / book
- 1.1×
- EV / EBITDA
- −7.7×
Cheaper than 88% of US stocks
Cheaper than 14% of US stocks
Cheaper than 70% of US stocks
Cheaper than 82% of US stocks
- Revenue growth (YoY)
- 247.3%
- Earnings growth (YoY)
- 247.3%
- Gross margin
- 99.9%
- Operating margin
- −54.3%
- Net margin
- −187.6%
Higher than 97% of US stocks
Higher than 93% of US stocks
Higher than 99% of US stocks
Higher than 17% of US stocks
Higher than 3% of US stocks
- Return on equity
- −20.3%
- Return on assets
- −11.3%
- Dividend yield
- —
Higher than 31% of US stocks
Higher than 26% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
OABI vs competitors
The nearest names by industry and size, scored by the same model — like for like.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. OABI appears on the weeks it earns a place.
Frequently asked questions about OABI stock
What is the OABI stock price forecast for 2026-2027?
The 7 Wall Street analysts covering OmniAb, Inc. have a median 12-month price target of $8, with estimates ranging from $3 to $11. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is OABI stock a buy right now?
Of the 7 analysts covering OmniAb, Inc., 7 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks OmniAb, Inc. 85 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank OABI?
As at 1 Aug 2026, OmniAb, Inc. ranks 85 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (91 of 100).
Will OABI stock go up?
No one can know that. What the data says: the median 12-month target from 7 analysts implies +308.2% from the last close, and Ticker Nerd's factor model ranks OmniAb, Inc. 85 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the OABI stock forecast for 2030?
No analyst covering OmniAb, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for OABI are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $3 to $11 over the next 12 months.
How has OABI stock performed over the past year?
OmniAb, Inc. returned +2.6% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
What does OmniAb, Inc. do?
OmniAb, Inc. is a biotechnology company that specializes in the discovery and development of therapeutic antibodies.
About OmniAb, Inc.
OmniAb, Inc. is a biotechnology company that specializes in the discovery and development of therapeutic antibodies. The company uses its proprietary technology platform, which leverages genetically engineered animals to generate a diverse range of antibodies. These antibodies are crucial for the development of drugs that can target a variety of diseases, ranging from cancer to autoimmune disorders. OmniAb collaborates with numerous pharmaceutical and biotech companies to create solutions that foster innovative treatments. One of the core features of OmniAb is its ability to streamline and enhance the drug discovery process, providing partners with access to high-quality antibodies. The company operates in a sector that is critical to advancing medical science and addressing some of the world's most challenging health conditions. By focusing on robust, versatile antibody generation, OmniAb plays a significant role in the pharmaceutical supply chain, ensuring that new therapies are both effective and efficient. In the financial market, OmniAb represents a part of the growing biotechnology industry, which is pivotal in driving advancements in medicine and increasing the longevity and quality of life. It stands as a notable innovator in the realm of antibody therapeutics.
CEO Mr. Matthew W. Foehr · 89 employees · United States · https://www.omniab.com